Zimmermann, Hanne M. L. http://orcid.org/0000-0002-1647-8485
Postma, Lisa R.
Achterbergh, Roel C. A.
Reyniers, Thijs
Schim van der Loeff, Maarten F.
Prins, Maria
de Vries, Henry J. C.
Hoornenborg, Elske
Davidovich, Udi
,
Funding for this research was provided by:
ZonMW (522002003)
National Institute for Public Health and the Environment
Aidsfonds Netherlands (2013169)
Gilead Sciences (CO-NL-276-4222, CO-US-276-1712)
Janssen Pharmaceuticals (PHNL/JAN/0714/0005b/1912fde)
MAC AIDS Fund
ViiV Healthcare (PO numbers: 3000268822, 3000747780)
Stichting Amsterdam Diner Foundation
Article History
Received: 11 December 2019
Revised: 31 August 2020
Accepted: 3 September 2020
First Online: 22 February 2021
Compliance with Ethical Standards
:
: Our institute received the drugs for the Amsterdam PrEP study from Gilead Sciences based on an unconditional grant. E.H. received financial reimbursement for time spent serving on advisory boards of Gilead Sciences and a speaker fee from Janssen-Cilag, paid to her institute. M.P. obtained unrestricted research grants and speaker’s fees from Gilead Sciences, Roche, Abbvie, and MSD, paid to her institute. U.D. obtained unrestricted research grants and speaker’s fees from Gilead Sciences paid to his institute. The remaining authors declared no potential conflicts of interests for this project.
: The AMPrEP protocol obtained medical approval from the ethics board of the Amsterdam UMC at the Academic Medical Center, Amsterdam, the Netherlands (NL49504.018.14). All AMPrEP participants provided written informed consent for the AMPrEP study, which included consent to be approached for interview requests. Participation in interviews for the present study was completely voluntary, and additional oralinformed consent for the recording, storage, and usage of interviews was obtained from all interviewees. The collected data were anonymize. Personal identiiers were deleted from the transcript, and only the researchers had access to anonymize transcripts.
: All AMPrEP participants provided written informed consent for the AMPrEP study, which included consent to be approached for interview requests. Participation in interviews for the present study was completely voluntary, and additional oral informed consent for the recording, storage and usage of interviews was obtained from all interviewees. The collected data were anonymized. Personal identifiers were deleted from the transcript, and only the researchers had access to anonymized transcripts.